Showing 43,281 - 43,300 results of 111,461 for search '(( 5 ((ppm decrease) OR (a decrease)) ) OR ( a ((fold decrease) OR (point decrease)) ))', query time: 1.34s Refine Results
  1. 43281

    The kinetics of the linear component affect the peak frequency of a bell shaped response. by Patrick A. Fletcher (583336)

    Published 2014
    “…(<b>B</b>) The corresponding bell-shaped responses have a peak that shifts to the right accordingly. (<b>C</b>) Duration compensation: increasing τ<sub>a</sub> shifts the response in </a><a><sub>on,∞</sub> and its K crossing point to the right. …”
  2. 43282
  3. 43283

    Image1_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf by Adrien Flahault (2602345)

    Published 2021
    “…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
  4. 43284

    Image1_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf by Adrien Flahault (2602345)

    Published 2021
    “…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
  5. 43285

    Image2_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf by Adrien Flahault (2602345)

    Published 2021
    “…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
  6. 43286

    Image2_LIT01-196, a Metabolically Stable Apelin-17 Analog, Normalizes Blood Pressure in Hypertensive DOCA-Salt Rats via a NO Synthase-dependent Mechanism.pdf by Adrien Flahault (2602345)

    Published 2021
    “…LIT01-196 behaves as a potent full agonist for the apelin receptor and has an in vivo half-life in the bloodstream of 28 min after intravenous (i.v.) and 156 min after subcutaneous (s.c.) administrations in conscious normotensive rats. …”
  7. 43287
  8. 43288

    DataSheet_1_Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis.pdf by Zaigham Abbas Rizvi (6167057)

    Published 2022
    “…Prophylactic treatment with GG showed protection against loss in body weight and a 35%–40% decrease in lung viral load along with reduced lung pathology in the hamster model. …”
  9. 43289

    Adipose-derived stem cells attenuate pulmonary microvascular hyperpermeability after smoke inhalation by Koji Ihara (4495504)

    Published 2017
    “…Sheep were randomly allocated to two groups: 1) ASCs: infused with 200 million of ASCs in 200mL of PlasmaLyteA starting 1 hours post-injury, n = 5; 2) control, treated with 200mL of PlasmaLyteA in a similar pattern, n = 5.…”
  10. 43290

    Image_2_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif by Qin Zeng (166641)

    Published 2022
    “…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
  11. 43291

    Illustration of three simple scenarios of association between genotype and a bivariate phenotype. by Matthew Stephens (3815)

    Published 2013
    “…A) A variant associated with <i>weight</i> but not <i>height</i>. …”
  12. 43292

    Image_1_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif by Qin Zeng (166641)

    Published 2022
    “…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
  13. 43293

    Inc exhibits key properties of a Cul3 adaptor in neurons in vivo. by Qiuling Li (390393)

    Published 2025
    “…<p><b>(A)</b> Co-immunoprecipitation of 3×FLAG-Inc and 3×FLAG-3×HA-Cul3 from male whole animal lysates. …”
  14. 43294

    Image_4_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif by Qin Zeng (166641)

    Published 2022
    “…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
  15. 43295

    Associations between HbA1c levels and mortality and diabetes complications. by Haipeng Ma (6792266)

    Published 2025
    “…The risk increases steadily with increasing HbA1c levels, with no clear inflection point. D: RCS curves for CKD risk. …”
  16. 43296

    Image_6_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif by Qin Zeng (166641)

    Published 2022
    “…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
  17. 43297

    Image_3_Identification of Sorafenib as a Treatment for Type 1 Diabetes.tif by Qin Zeng (166641)

    Published 2022
    “…Since sorafenib is classified as an FDA-approved drug, it serves as a preliminary lead point for additional experimentation and may be a promising therapy for type 1 diabetes in humans.…”
  18. 43298
  19. 43299
  20. 43300